Search

Codexis Inc

Закрыт

СекторЗдравоохранение

1.66 6.41

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

1.56

Макс.

1.69

Ключевые показатели

By Trading Economics

Доход

-3.3M

-12M

Продажи

-333K

15M

Прибыль на акцию

-0.13

Рентабельность продаж

-80.489

Сотрудники

146

EBITDA

-4.3M

-11M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+343.04% upside

Дивиденды

By Acuity

Следующий отчет о доходах

5 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

13M

174M

Предыдущая цена открытия

-4.75

Предыдущая цена закрытия

1.66

Новостные настроения

By Acuity

31%

69%

110 / 340 Рейтинг в Healthcare

Codexis Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

20 авг. 2026 г., 19:16 UTC

Codexis Inc. shares are roughly flat as no specific news emerged. Intraday fluctuations ranged from a high of 8.23% to a low of -1.27%.

19 авг. 2026 г., 20:02 UTC

Correlated Moves
News

Codexis Inc shares are higher today, supported by positive momentum in the genomics sector and the performance of the ARK Genomic Revolution ETF.

18 авг. 2026 г., 19:41 UTC

Codexis Inc shares are trading lower during Tuesday's session, continuing a decline since Monday's close amid broader market concerns over rising treasury yields and inflation.

17 авг. 2026 г., 19:56 UTC

News

Codexis shares are higher as Piper Sandler maintains Overweight rating and lowers price target to $8.00 from $9.00. Positive investor sentiment persists.

14 авг. 2026 г., 19:46 UTC

Codexis Inc shares are lower, reflecting broader market weakness amid an unexpected decline in U.S. retail sales for July.

13 авг. 2026 г., 19:51 UTC

News

Codexis reported Q2 2026 revenue of $14.9 million and a net loss of $12.0 million. Shares are trading roughly flat during Thursday's session.

12 авг. 2026 г., 20:01 UTC

News

Codexis reported a narrower net loss of $12 million and reaffirmed revenue guidance of $72 million to $76 million, contributing to gains during Wednesday's session.

11 авг. 2026 г., 23:51 UTC

News

Codexis reported second-quarter revenues of $14.9 million, exceeding estimates. Shares are trading higher in after-market hours following the positive earnings report and guidance.

10 авг. 2026 г., 19:21 UTC

News

Codexis Inc shares are higher following a positive earnings report, with a loss per share of -$0.10, better than analysts' expectations of -$0.11.

7 авг. 2026 г., 19:36 UTC

Codexis Inc shares are lower, reflecting broader market trends amid uncertainty over monetary policy and a weaker-than-expected jobs report.

6 авг. 2026 г., 19:56 UTC

Codexis Inc shares are higher during Thursday's session, continuing an upward trend. The stock remains below its 20-day moving average.

5 авг. 2026 г., 20:06 UTC

Codexis Inc shares are higher today, reflecting positive market sentiment amid a broader uptick in equities. No specific news was identified for the movement.

4 авг. 2026 г., 19:56 UTC

Codexis Inc. shares are trading roughly flat, with no specific news identified. The stock remains below its 20-day moving average and near its one-month range low.

3 авг. 2026 г., 19:44 UTC

News

Codexis Inc has appointed David Butler, PhD, to its Strategic Advisory Board. Shares are advancing, though still below the 20-day moving average.

31 июл. 2026 г., 20:02 UTC

Codexis Inc shares are trading lower today, continuing a broader decline. The stock is near the lower end of its one-month range.

30 июл. 2026 г., 20:09 UTC

Codexis Inc shares are higher today, continuing their rise since Wednesday's close. Broader market volatility is influenced by mixed economic signals.

29 июл. 2026 г., 19:47 UTC

Macro Event

Codexis Inc shares are lower amid broader market declines and heightened volatility following the Federal Reserve's decision to keep interest rates steady.

28 июл. 2026 г., 19:51 UTC

Codexis Inc. shares are trading lower today, reflecting a downward trend since Monday, with a notable decline from an earlier session high.

27 июл. 2026 г., 19:21 UTC

News

Codexis Inc shares are higher today, supported by early customer orders and interest from CDMOs. The stock remains up since Friday's close.

24 июл. 2026 г., 19:01 UTC

News

Codexis Inc shares are lower following a public offering of 16.67 million shares at $1.50 each, below Thursday's close of $1.99.

23 июл. 2026 г., 23:51 UTC

News

Codexis Inc announced a public offering of common stock, contributing to a notable decline in shares during after-market trading.

22 июл. 2026 г., 20:01 UTC

Codexis Inc shares are lower during Wednesday's session, continuing a trend of declines since Tuesday's close. The stock remains below its 20-day moving average.

Сравнение c конкурентами

Изменение цены

Codexis Inc Прогноз

Целевая цена

By TipRanks

343.04% рост

Прогноз на 12 месяцев

Средняя 7 USD  343.04%

Максимум 11 USD

Минимум 2 USD

Основано на мнении 4 аналитиков Wall Street, спрогнозировавших целевые цены для Codexis Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

4 ratings

3

Покупка

1

Удержание

0

Продажа

Настроения

By Acuity

110 / 340Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Codexis Inc

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, the company is currently developing its proprietary ECO Synthesis(tm) manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
help-icon Live chat